SEQUENCE LISTING

```
<110> ITO, Kyogo
<120> An agent for preventing and/or treating hematologic malignancies
<130> 3190-090
<140> US Unassigned
<141> 2006-02-03
<150> PCT/JP2004/011232
<151> 2004-08-05
<150> JP P2003-287208
<151> 2003-08-05
<160> 12
<170> PatentIn version 3.1
<210> 1
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Partial peptide of p56lck protein
<400> 1
His Tyr Thr Asn Ala Ser Asp Gly Leu
<210> 2
<211> 10
<212> PRT
<213> Artificial
<220>
<223> Partial peptide of p56lck protein
<400> 2
Asp Tyr Leu Arg Ser Val Leu Glu Asp Phe
<210> 3
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Partial peptide of p56lck protein
<400> 3
Thr Phe Asp Tyr Leu Arg Ser Val Leu
```

```
<210> 4
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Partial peptide of SART-1
<400> 4
Glu Tyr Arg Gly Phe Thr Gln Asp Phe
<210> 5
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Partial peptide of SART-2
<400> 5
Asp Tyr Ser Ala Arg Trp Asn Glu Ile
<210> 6
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Partial peptide of SART-2
<400> 6
Ala Tyr Asp Phe Leu Tyr Asn Tyr Leu
       5
<210> 7
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Partial peptide of SART-2
<400> 7
Ser Tyr Thr Arg Leu Phe Leu Ile Leu
               5
<210> 8
<211> 10
<212> PRT
<213> Artificial
<220>
<223> Partial peptide of SART-3
```

```
<400> 8
Val Tyr Asp Tyr Asn Cys His Val Asp Leu
<210> 9
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Partial peptide of SART-3
<400> 9
Ala Tyr Ile Asp Phe Glu Met Lys Ile
<210> 10
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Partial peptide of ART-1
<400> 10
Glu Tyr Cys Leu Lys Phe Thr Lys Leu
         5
<210> 11
<211> 11
<212> PRT
<213> Artificial
<223> Human Immunodeficiency Virus-derived peptide
<400> 11
Arg Tyr Leu Arg Asp Gln Gln Leu Leu Gly Ile
<210> 12
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Epstein-Barr-Virus-derived peptide
<400> 12
Thr Tyr Gly Pro Val Phe Met Cys Leu
```